Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists

References

• Bolla M, Maingon P, Carrie C, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34(15):1748–1756. doi: 10.1200/JCO.2015.64.8055.
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–1290. doi: 10.1016/j.ijrobp.2004.08.047.
   PubMed Web of Science ®Google Scholar
• Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–459. doi: 10.1016/S1470-2045(11)70063-8.
   PubMed Web of Science ®Google Scholar
• Kishan AU, Sun Y, Hartman H, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022;23(2):304–316. doi: 10.1016/S1470-2045(21)00705-1.
   PubMed Web of Science ®Google Scholar
• O'Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–1251. doi: 10.1200/JCO.2014.59.1792.
   PubMed Web of Science ®Google Scholar
• Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer. 2016;16(1):180. doi: 10.1186/s12885-016-2221-5.
   PubMedGoogle Scholar
• Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–396. doi: 10.1016/j.eururo.2014.11.039.
   PubMed Web of Science ®Google Scholar
• Scailteux LM, Vincendeau S, Balusson F, et al. Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French health insurance data. Eur J Cancer. 2017;77:99–108. doi: 10.1016/j.ejca.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–836. doi: 10.1016/j.eururo.2014.07.010.
   PubMed Web of Science ®Google Scholar
• European Association of Urology. Prostate cancer treatment 2021. Available from: https://uroweb.org/guideline/prostate-cancer/#6.
   Google Scholar
• Regionala Cancercentrum i Samverkan. Nationellt vårdprogram prostatacancer 2022. Available from: https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/prostatacancer/vardprogram/nvp-prostatacancer.pdf.
   Google Scholar
• Stattin P, Sandin F, Hellström K, et al. The national prostate cancer register of Sweden. Tijdschr Urol. 2017;7(2-3):50–59. doi: 10.1007/s13629-017-0168-1.
   Google Scholar
• Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the national prostate cancer register of Sweden. Eur J Cancer. 2015;51(1):101–111. Jandoi: 10.1016/j.ejca.2014.10.025.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: the national prostate cancer register of Sweden and prostate cancer data base–a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73–82. doi: 10.1093/ije/dyv305.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: the national prostate cancer register of Sweden and prostate cancer data base Sweden 2.0. Int J Epidemiol. 2013;42(4):956–967. doi: 10.1093/ije/dys068.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):450. doi: 10.1186/1471-2458-11-450.
   PubMed Web of Science ®Google Scholar
• Fall K, Strömberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42(4):352–357. doi: 10.1080/00365590802078583.
   PubMed Web of Science ®Google Scholar
• Brooke HL, Talbäck M, Hörnblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–773. doi: 10.1007/s10654-017-0316-1.
   PubMed Web of Science ®Google Scholar
• Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the swedish prescribed drug register – a systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119(5):464–469. doi: 10.1111/bcpt.12613.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Svedberg P, Olén O, et al. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423–437. doi: 10.1007/s10654-019-00511-8.
   PubMed Web of Science ®Google Scholar
• Glasheen WP, Cordier T, Gumpina R, et al. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019; 12(4):188–197.
   PubMed Web of Science ®Google Scholar
• Tanskanen A, Taipale H, Koponen M, et al. Drug exposure in register-based research-An expert-opinion based evaluation of methods. PLoS One. 2017;12(9):e0184070. doi: 10.1371/journal.pone.0184070.
   PubMed Web of Science ®Google Scholar
• Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505. doi: 10.6004/jnccn.2019.0023.
   PubMed Web of Science ®Google Scholar
• McGivern U, Mitchell DM, McDowell C, et al. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis. Clin Genitourin Cancer. 2012; 10(3):190–195. doi: 10.1016/j.clgc.2012.04.003.
   PubMed Web of Science ®Google Scholar
• Buwenge M, Deodato F, Macchia G, et al. Radiotherapy Plus GnRH analogue Versus high dose bicalutamide: a case control study. Anticancer Res. 2019; 39(11):6373–6378. doi: 10.21873/anticanres.13850.
   PubMed Web of Science ®Google Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886. doi: 10.1056/NEJM200006223422506.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060. doi: 10.1016/S1470-2045(16)30102-4.
   PubMed Web of Science ®Google Scholar